Company: SVREW
Filing Date: 2025-01-31
Form Type: 424B5
Source: 0001213900-25-008656
Chunk: 21

Company: SaverOne 2014 Ltd.
Filing Date: 2025-01-31
Form: 424B5
Chunk 21
---
 affect our ability to develop and commercialize
our products. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to
us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders and the issuance
of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our ADSs
and ordinary shares to decline. The incurrence of indebtedness could result in increased fixed payment obligations, and we may be required
to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to
acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct
our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage
than otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or products or otherwise agree
to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. Even if
we believe that we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions
are favorable or if we have specific strategic considerations.

If
we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our
research or development programs or the commercialization of our SaverOne systems or be unable to expand our operations or otherwise
capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of
operations.

A substantial number of ADSs will be sold in this offering, which could cause the price of our ADSs and ordinary shares to decline.

In
this offering, we expect to sell 2,171,433 ADSs representing 195,428,970 ordinary shares which represent approximately
28.9 % of our outstanding ordinary shares as of January 31, 2025. This sale and any future sales of a substantial number of ADSs or ordinary
shares in the public market, or the perception that such sales may occur, could adversely affect the price of the ADSs on the Nasdaq
Capital Market or our ordinary shares on the TASE. We cannot predict the effect, if any, that market sales of those ADSs or ordinary
shares or the availability of those